Id Biomedical Corporation

Id Biomedical Corporation of Quebec

Biochem Pharma Inc.

Biochem Vaccines Inc.

Denis Martin

Bernard R Brodeur

Josee Hamel

Josée Hamel

Clement Rioux

Stephane Rioux

Martine Boyer

Patrick Rheault

Nathalie Charland

Stéphane Rioux

Isabelle Charlebois

Isabelle Pineau

Julie Couture

Clément Rioux

Catherine Ouellet

Diane Bussiere

Normand Blais

Steve Labbe

Annie Charbonneau

Mireille Tremblay

The present invention relates to antigens more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.

Streptococcus pyogenes antigens and corresponding DNA fragments

The present invention relates to antigens, more particularly antigenS of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.

[object Object]

Group B(GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

The present invention relates to antigens, more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.

proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

Group B(GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Group B streptococcus antigens

The present invention relates to antigens, more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.

The identification of a highly conserved, immunologically accessible antigen at the surface offacilitates treatment, prophylaxis, and diagnosis ofdiseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from threestrains and from onestrain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of thesurface protein, and antibodies that bind to this protein are also disclosed.

The present invention relates to antigens, more particularly an antigen of(also called group A(GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.

The present invention relates to antigens, more particularly antigens of Group B(GBS) () which may be useful to prevent, diagnose and/or treat streptococcal infections.

Growing community of inventors

St-Augustin-de-Desmaures, Canada

Denis Martin